Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone (“VCD-Lite”) in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma

Smith, 2009, Future of cancer incidence in the United States: burdens upon an aging, changing nation, J Clin Oncol, 27, 2758, 10.1200/JCO.2008.20.8983 Turesson, 2010, Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic, Mayo Clin Proc, 85, 225, 10.4065/mcp.2009.0426 Palumbo, 2010, Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial, J Clin Oncol, 28, 5101, 10.1200/JCO.2010.29.8216 San Miguel, 2008, Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma, N Engl J Med, 359, 906, 10.1056/NEJMoa0801479 Magarotto, 2016, Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma, Blood, 127, 1102, 10.1182/blood-2015-08-662627 Larocca, 2015, How I treat fragile myeloma patients, Blood, 126, 2179, 10.1182/blood-2015-05-612960 Palumbo, 2011, Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN), Blood, 118, 4519, 10.1182/blood-2011-06-358812 Barlogie, 2014, Curing myeloma at last: defining criteria and providing the evidence, Blood, 124, 3043, 10.1182/blood-2014-07-552059 Niesvizky, 2015, Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens, J Clin Oncol, 10.1200/JCO.2014.58.7618 Hulin, 2016, Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial, J Clin Oncol, 34, 3609, 10.1200/JCO.2016.66.7295 Reeder, 2009, Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial, Leukemia, 23, 1337, 10.1038/leu.2009.26 Reeder, 2014, Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma, Br J Haematol, 167, 563, 10.1111/bjh.13004 Moreau, 2008, Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma, Haematologica, 93, 1908, 10.3324/haematol.13285 Bringhen, 2010, Efficacy and safety of once-weekly bortezomib in multiple myeloma patients, Blood, 116, 4745, 10.1182/blood-2010-07-294983 Extermann, 2012, Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score, Cancer, 118, 3377, 10.1002/cncr.26646 Hurria, 2011, Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study, J Clin Oncol, 29, 3457, 10.1200/JCO.2011.34.7625 Palumbo, 2015, Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international myeloma working group report, Blood, 125, 2068, 10.1182/blood-2014-12-615187 Hall, 2004, An electronic application for rapidly calculating Charlson comorbidity score, BMC Cancer, 4, 94, 10.1186/1471-2407-4-94 Rajkumar, 2011, Consensus recommendations for the uniform reporting of clinical trials: report of the international myeloma workshop consensus panel 1, Blood, 117, 4691, 10.1182/blood-2010-10-299487 Greipp, 2005, International staging system for multiple myeloma, J Clin Oncol, 23, 3412, 10.1200/JCO.2005.04.242 Palumbo, 2015, Revised international staging system for multiple myeloma: a report from international myeloma working group, J Clin Oncol, 10.1200/JCO.2015.61.2267 San-Miguel, 2008, Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study, Leukemia, 22, 842, 10.1038/sj.leu.2405087 Moreau, 2016, VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial, Blood, 127, 2569, 10.1182/blood-2016-01-693580 Durie, 2015, Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial S, Blood, 126, 25, 10.1182/blood.V126.23.25.25 O'Donnell, 2014, A phase II study of modified lenalidomide, bortezomib, and dexamethasone (RVD lite) for transplant-ineligible patients with newly diagnosed multiple myeloma, Blood, 124, 3454, 10.1182/blood.V124.21.3454.3454